Quotes 5-day view Real-time Euronext Paris
09/20/2021
09/21/2021
09/22/2021
09/23/2021
09/24/2021
Date
2.465(c)
2.48(c)
2.54(c)
2.57(c)
2.45(c)
Last
165 387
51 516
73 858
141 253
78 020
Volume
-3.33% +0.61% +2.42% +1.18% -4.67% Change
Estimated financial data (e) EUR USD
Sales 2021
11,1 M 13,0 M 13,0 M
Net income 2021
-27,0 M -31,6 M -31,6 M
Net cash position 2021
44,7 M 52,4 M 52,4 M
P/E ratio 2021
-8,75x
Yield 2021
-
Sales 2022
8,10 M 9,49 M 9,49 M
Net income 2022
-32,5 M -38,1 M -38,1 M
Net cash position 2022
12,7 M 14,9 M 14,9 M
P/E ratio 2022
-7,42x
Yield 2022
-
Capitalization
239 M 280 M 280 M
EV / Sales 2021
17,5x
EV / Sales 2022
27,9x
Nbr of Employees
139
Free-Float
51,4%
Transgene SA is a biopharmaceutical company. The Company designs and develops immunotherapy products to treat cancer and infectious diseases. These products use viral vectors to directly or indirectly destroy diseased cells. The Company has approximately three products in clinical development: two immunotherapy products for cancer treatment and an anti-infective immunotherapy product for chronic hepatitis B. The...
09/23 Certain Ordinary Shares of Transgene SA are subject to a Lock-Up Agreement Ending on 23.. CI
09/16 TRANSGENE : Gastrointestinal Cancer Drug Study Confirms Potential of Cancer-Killing VirusMT
09/16 Transgene Presents Data from Phase I Clinical Trial Confirming the Potential of the Onc.. CI
09/13 GLOBAL MARKETS LIVE : Valneva, Walt Disney, ViacomCBS, General Motors, Amazon...09/07 PRESS RELEASE : CEVEC and UCB sign agreement for the use of CEVEC's ELEVECTA(R) AAV manufa..DJ
09/02 GLOBAL MARKETS LIVE : Ford, Walmart, Apple, Volkswagen, Tesla...09/01 Transgene Participates in New Cancer Research Consortium CI
06/28 Transgene Announces Update on Phase I Clinical Trial of TG4050 CI
06/25 GLOBAL MARKETS LIVE : Facebook, Toshiba, Fedex, Nike, Microsoft...06/24 Transgene announces First Patient Enrolled in Expanded Phase II Clinical Trial of Tg400.. CI
06/22 GLOBAL MARKETS LIVE : Netflix, Boeing, Tesla, Delta Air Lines, Blackstone Resources....06/22 TRANSGENE : Raises $40.6 Million in Share Sale; Stock Falls 7%MT
06/22 TRANSGENE : Admission of new securitiesCO
06/08 Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses En.. CI
05/27 BioInvent, Transgene Win US FDA Nod For Phase 1/2a Study of Cancer Vaccine MT
News in other languages on TRANSGENE
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends TRANSGENE
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2,45 €
Average target price
3,80 €
Spread / Average Target
55,1%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
